BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29472312)

  • 21. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
    Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
    Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
    Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
    J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
    Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
    J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
    Sobecki-Rausch J; Barroilhet L
    Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
    Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
    Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
    Wong RW; Cheung ANY
    Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
    Green AK; Feinberg J; Makker V
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome.
    Mas-Moya J; Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Hum Pathol; 2015 Nov; 46(11):1616-25. PubMed ID: 26319271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
    Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
    Kasherman L; Ahrari S; Lheureux S
    Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
    Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Approved Use for Keytruda.
    Aschenbrenner DS
    Am J Nurs; 2022 Jul; 122(7):26-27. PubMed ID: 35736598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
    Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
    Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
    Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
    Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
    Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.